Diabetic patients taking oral fluoroquinolones, a frequently prescribed class of antibiotics, were found to have a higher risk of severe blood sugar-related problems than diabetic patients taking other kinds of antibiotics, according to a recent study from Taiwan published in Clinical Infectious Diseases. The increased risk was low—hyperglycemia (high blood sugar) or hypoglycemia (low blood sugar) related to the drugs occurred in fewer than one in 100 patients studied—but clinicians should consider the higher risk when treating diabetic patients with fluoroquinolones, especially moxifloxacin, and prescribe them cautiously, the study’s authors concluded.
Increased use of these drugs, commonly used to treat such illnesses as urinary tract infections and community-acquired pneumonia, has raised concerns about rare but severe adverse effects, including tendon rupture and heart arrhythmia. Previous studies have also indicated a relationship between fluoroquinolones and severe glucose-related abnormalities, known as dysglycemia, which includes hyperglycemia or hypoglycemia. Severe blood sugar swings can lead to serious health problems, including irreversible brain damage or even death. In 2006, one drug from the fluoroquinolone class, gatifloxacin, was withdrawn from the U.S. market due to the risk of blood sugar abnormalities.
To assess the risk of blood sugar swings in diabetic patients using specific fluoroquinolones, a team of researchers, led by Mei-Shu Lai, MD, PhD, at National Taiwan University in Taipei, conducted a population-based cohort study of approximately 78,000 people with diabetes in Taiwan from January 2006 to November 2007.
Using the claims database for Taiwan’s national insurance program, the researchers analyzed data for diabetic outpatients who had received a new prescription for an antibiotic from one of three different classes of antibiotics: fluoroquinolones (levofloxacin, ciprofloxacin, or moxifloxacin); second-generation cephalosporins (cefuroxime, cefaclor, or cefprozil); or macrolides (clarithromycin or azithromycin). The study’s authors then looked for any emergency department visits or hospitalizations for dysglycemia among these patients within 30 days of the start of their antibiotic therapy.
Diabetics using oral fluoroquinolones faced greater risk of severe blood sugar swings than diabetic patients using antibiotics in other classes, the researchers found. The risks varied according to the specific fluoroquinolone the patients were using: The absolute risk, or incidence, of hyperglycemia per 1,000 people studied was 6.9 for moxifloxacin, 3.9 for levofloxacin, and 4.0 for ciprofloxacin. The absolute risk of hypoglycemia was 10.0 for moxifloxacin, 9.3 for levofloxacin, and 7.9 for ciprofloxacin.
(By comparison, among diabetic patients taking antibiotics in the macrolides class, the absolute risk of hyperglycemia was lower, at 1.6 per 1,000, and 2.1 per 1,000 among those taking antibiotics in the cephalosporin class; for hypoglycemia, the absolute risk per 1,000 was 3.7 for macrolides and 3.2 for cephalosporins, respectively.)
“Our results identified moxifloxacin as the drug associated with the highest risk of hypoglycemia, followed by levofloxacin and ciprofloxacin,” the study’s authors wrote. “Other antibiotics should be considered if dysglycemia is a concern, such as a beta lactam or macrolide,” noted Dr. Lai.
The study is available online:Risk of Severe Dysglycemia Among Diabetic Patients Receiving Levofloxacin, Ciprofloxacin, or Moxifloxacin in Taiwanhttp://cid.oxfordjournals.org/content/early/2013/07/23/cid.cit439.full
Clinical Infectious Diseases is a leading journal in the field of infectious disease with a broad international readership. The journal publishes articles on a variety of subjects of interest to practitioners and researchers. Topics range from clinical descriptions of infections, public health, microbiology, and immunology to the prevention of infection, the evaluation of current and novel treatments, and the promotion of optimal practices for diagnosis and treatment. The journal publishes original research, editorial commentaries, review articles, and practice guidelines and is among the most highly cited journals in the field of infectious diseases. Clinical Infectious Diseases is an official publication of the Infectious Diseases Society of America (IDSA). Based in Arlington, Va., IDSA is a professional society representing nearly 10,000 physicians and scientists who specialize in infectious diseases. For more information, visit www.idsociety.org.
1300 Wilson Boulevard Suite 300 Arlington, VA 22209 | Phone: (703) 299-0200 | Fax: (703) 299-0204
| HIVMA | Contact Us
© Copyright IDSA 2015 Infectious Diseases Society of America